Join us July 9th and 10th for the KAND Family & Scientific Engagement Conference hosted by KIF1A.ORG. Register here to join the conversation and learn about the latest research and development efforts towards bringing treatments to those affected by KIF1A-Associated Neurological Disorder (KAND).
BioLoomics Founder & CEO, Dr. Doug Chapnick, will present an overview of our evolution-in-a-microscope technology, and describe how we are leveraging it to build a KAND treatment pipeline.
Thank you to KIF1A.ORG for hosting and for creating a unique opportunity to share research insights across companies, institutions, and with those who care for people affected by KAND every day.